Andrew Thorley is the Director of Fibrosis, Nephrology & COPD at Genentech, where they also serve as Principal Scientist Group Leader in OMNI Biomarker Development. Prior to this, Andrew was a Principal Scientist II at Novartis Institutes for BioMedical Research from 2018 to 2020. Andrew's academic career included roles as Assistant Professor, Academic Fellow, and Honorary Assistant Professor at Imperial College London from 2011 to 2017. Andrew earned a PhD in Respiratory Medicine from Imperial College London and an MPharmacol in Pharmacology from the University of Bath.
This person is not in the org chart
This person is not in any teams
This person is not in any offices